Erratum: CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer (Journal of Clinical Oncology DOI: 10.1200/JCO.2017.76.6212);CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer

Journal of Clinical Oncology

Volumn 36, Issue 28, 2018, Pages 2836-2844

  Janjigian, Yelena Y ^a   Bendell, Johanna ^b   Calvo, Emiliano ^c   Kim, Joseph W ^d   Ascierto, Paolo A ^e   Sharma, Padmanee ^g   Ott, Patrick A ^h   Peltola, Katriina ⁱ   Jaeger, Dirk ^j   Evans, Jeffry ^k   De Braud, Filippo ^f   Chau, Ian ^l,m   Harbison, Christopher T ⁿ   Dorange, Cecile ⁿ   Tschaika, Marina ⁿ   Le, Dung T ^o  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c START   (Spain)

^d YALE CANCER CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ International Comprehensive Cancer Center Docrates   (Finland)

^j UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^k UNIVERSITY OF GLASGOW   (United Kingdom)

^l ROYAL MARSDEN HOSPITAL   (United Kingdom)

^m ROYAL MARSDEN HOSPITAL   (United Kingdom)

ⁿ BRISTOL MYERS SQUIBB   (United States)

^o JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT;

ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FATIGUE; FEMALE; FOLLOW UP; GASTROESOPHAGEAL JUNCTION; HUMAN; HYPERTRANSAMINASEMIA; LIVER METASTASIS; LONG TERM SURVIVAL; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PERITONEUM METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; STOMACH CANCER; SURVIVAL RATE; TREATMENT RESPONSE; TREATMENT RESPONSE TIME; TUMOR LYSIS SYNDROME; TUMOR VOLUME; ADENOCARCINOMA; CLINICAL TRIAL; ESOPHAGUS TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; IPILIMUMAB; MALE; MIDDLE AGED; NIVOLUMAB; PROGRESSION-FREE SURVIVAL; YOUNG ADULT;

EID: 85053083958     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.18.02406     Document Type: Erratum

References (28)

1. International Agency for Research on Cancer: Stomach cancer: GLOBOCAN 2012: Estimated incidence, mortality and prevalence worldwide in 2012. Http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx?cancer=stomach
2. International Agency for Research on Cancer: Oesophageal cancer: GLOBOCAN 2012: Estimated incidence, mortality and prevalence. Http://globocan. Iarc.fr/Pages/fact-sheets-cancer.aspx?cancer= oesophagus
3. Anandappa G, Chau I: Emerging novel therapeutic agents in the treatment of patients with gastroesophageal and gastric adenocarcinoma. Hematol Oncol Clin North Am 31:529-544, 2017
4. Wagner AD, Syn NL, Moehler M, et al: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 8:CD004064, 2017
5. Janjigian YY, Sanchez-Vega F, Jonsson P, et al: Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov 8:49-58, 2018
6. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202-209, 2014
7. Cancer Genome Atlas Research Network: Integrated genomic characterization of oesophageal carcinoma. Nature 541:169-175, 2017
8. Zhang M, Dong Y, Liu H, et al: The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: A meta-analysis of 10 studies with 1,901 patients. Sci Rep 6:37933, 2016
9. Muro K, Chung HC, Shankaran V, et al: Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, openlabel, phase 1b trial. Lancet Oncol 17:717-726, 2016
10. Fuchs CS, Doi T, Jang RW, et al: Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 4:e180013; 2018
11. Janjigian Y, Bendell JC, Calvo E, et al: CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (NIVO) alone or with ipilimumab (IPI) in advanced and metastatic (A/M) gastric cancer (GC). J Clin Oncol 34, 2016 (suppl; abstr 4010)
12. Kang YK, Boku N, Satoh T, et al: Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390: 2461-2471, 2017
13. Curran MA, Montalvo W, Yagita H, et al: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107:4275-4280, 2010
14. Selby M, Englehardt J, Lu L-S, et al: Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. J Clin Oncol 31, 2013 (suppl; abstr 3061)
15. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373: 23-34, 2015
16. Antonia SJ, Lopez-Martin JA, Bendell J, et al: Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial. Lancet Oncol 17:883-895, 2016
17. Overman MJ, Lonardi S, Wong KYM, et al: Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36:773-779, 2018
18. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
19. National Cancer Institute: NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Bethesda, MD, National Cancer Institute, 2009
20. Umar A, Boland CR, Terdiman JP, et al: Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96: 261-268, 2004
21. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
22. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133, 2013
23. Hammers HJ, Plimack ER, Infante JR, et al: Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: The CheckMate 016 Study. J Clin Oncol 35:3851-3858, 2017
24. Hellmann MD, Rizvi NA, Goldman JW, et al: Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): Results of an openlabel, phase 1, multicohort study. Lancet Oncol 18:31-41, 2017
25. Muro K, Fuchs CS, Jang RW, et al: KEYNOTE-059 cohort 1: Pembrolizumab (Pembro) monotherapy in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer in patients (Pts) with PD-L1+ tumors: Asian subgroup analysis. J Clin Oncol 36, 2018 (suppl, abstr 723)
26. Opdivo (nivolumab) US prescribing information: Princeton, NJ, Bristol-Myers Squibb, 2018
27. Le DT, Durham JN, Smith KN, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409-413, 2017
28. Le DT, Uram JN,Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509-2520, 2015